Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Inovio Pharma (INO)

Inovio Pharma (INO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.7300 -0.0300 (-1.70%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.7600 +0.0300 (+1.73%) 19:56 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.6800
Day High
1.7700
Open 1.7600
Previous Close 1.7600 1.7600
Volume 634,100 634,100
Avg Vol 702,650 702,650
Stochastic %K 9.37% 9.37%
Weighted Alpha -79.62 -79.62
5-Day Change -0.1900 (-9.90%) -0.1900 (-9.90%)
52-Week Range 1.6800 - 14.7480 1.6800 - 14.7480
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,434
  • Shares Outstanding, K 36,667
  • Annual Sales, $ 220 K
  • Annual Income, $ -107,250 K
  • EBIT $ -112 M
  • EBITDA $ -109 M
  • 60-Month Beta 0.92
  • Price/Sales 296.03
  • Price/Cash Flow N/A
  • Price/Book 0.93

Options Overview Details

View History
  • Implied Volatility 151.03% ( -330.99%)
  • Historical Volatility 56.87%
  • IV Percentile 84%
  • IV Rank 22.92%
  • IV High 596.49% on 03/25/25
  • IV Low 18.57% on 08/26/24
  • Put/Call Vol Ratio 0.22
  • Today's Volume 67
  • Volume Avg (30-Day) 473
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 12,596
  • Open Int (30-Day) 13,807

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.73
  • Low Estimate -0.75
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +43.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6800 +2.98%
on 03/28/25
Period Open: 1.9800
2.1800 -20.64%
on 03/17/25
-0.2500 (-12.63%)
since 02/28/25
3-Month
1.6800 +2.98%
on 03/28/25
Period Open: 1.8700
2.3900 -27.62%
on 01/07/25
-0.1400 (-7.49%)
since 12/27/24
52-Week
1.6800 +2.98%
on 03/28/25
Period Open: 13.8800
14.7480 -88.27%
on 04/01/24
-12.1500 (-87.54%)
since 03/28/24

Most Recent Stories

More News
Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript

INO earnings call for the period ending December 31, 2024.

INO : 1.7300 (-1.70%)
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.Last week, Precigen announced that it has completed...

CTMX : 0.6282 (+1.88%)
PGEN : 1.5900 (-3.05%)
CSTL : 19.94 (-0.80%)
INO : 1.7300 (-1.70%)
Inovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail Sentiment

For the quarter ending September 30, Inovio reported a loss of $0.89 per share, beating analyst estimates of a $1.15 loss per share, according to Stocktwits data.

VXF : 172.98 (-2.07%)
VTI : 273.43 (-1.99%)
INO : 1.7300 (-1.70%)
IWM : 200.45 (-2.03%)
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript

INO earnings call for the period ending September 30, 2024.

INO : 1.7300 (-1.70%)
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish

Retail sentiment on the stock dipped to ‘bullish’ from ‘extremely bullish’ last week.

VXF : 172.98 (-2.07%)
VTI : 273.43 (-1.99%)
INO : 1.7300 (-1.70%)
IWM : 200.45 (-2.03%)
Inovio: Q3 Earnings Snapshot

Inovio: Q3 Earnings Snapshot

INO : 1.7300 (-1.70%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0007 (unch)
TNXP : 20.17 (-24.37%)
IBB : 130.29 (-0.98%)
JAGX : 5.00 (-7.06%)
NVAX : 7.00 (-3.58%)
INO : 1.7300 (-1.70%)
GILD : 111.79 (+0.57%)
MRNA : 31.12 (-3.11%)
VXRT : 0.4212 (-7.83%)
IBIO : 4.12 (-6.58%)
XBI : 84.40 (-1.32%)
PFE : 25.21 (+0.80%)
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END

SBFM : 2.00 (-4.76%)
MRNA : 31.12 (-3.11%)
PFE : 25.21 (+0.80%)
INO : 1.7300 (-1.70%)
VIR : 6.70 (+0.45%)
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

SBFM : 2.00 (-4.76%)
MRNA : 31.12 (-3.11%)
PFE : 25.21 (+0.80%)
INO : 1.7300 (-1.70%)
VIR : 6.70 (+0.45%)
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript

INO earnings call for the period ending June 30, 2024.

INO : 1.7300 (-1.70%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 1.8633
2nd Resistance Point 1.8167
1st Resistance Point 1.7733
Last Price 1.7300
1st Support Level 1.6833
2nd Support Level 1.6367
3rd Support Level 1.5933

See More

52-Week High 14.7480
Fibonacci 61.8% 9.7560
Fibonacci 50% 8.2140
Fibonacci 38.2% 6.6720
Last Price 1.7300
52-Week Low 1.6800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies